HROW News and Press, Harrow Health Inc. From 12/08/25

2025-12-08 11:31:49 ET The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days. We hope this provides ideas and inspires discussion among the community.... Read the full article on Seekin...

2025-12-01 08:00:00 ET ... Read the full article on Seeking Alpha For further details see: Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS

2025-11-25 17:30:02 ET Background I am a retired engineer. I have a diversified portfolio composed of equity funds, individual stocks, bond funds and individual stocks. I invest in bonds and dividend stocks to provide the cash flow required to fund my retirement. That said, ...

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Oph...

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering...

2025-11-11 14:12:31 ET More on Harrow Health Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other Harrow Health ...

2025-11-11 14:11:32 ET Harrow, Inc. (HROW) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO &a...

2025-11-11 10:30:53 ET Harrow Health, Inc. (NASDAQ: HROW) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 4.16% on the day to $35.56. Harrow Health, Inc. operates as an ophthalmic-focused healthcare com...

2025-11-10 16:11:49 ET More on Harrow Health Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other Harrow, Inc. (HROW) Analyst/Investor Day Transcript Harrow Health Q...

Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 3...